Promoters of Unichem Laboratories have confirmed that no encumbrance has been created on the equity shares held by them for the financial year ended March 31, 2026. The declaration, submitted to the stock exchanges, assures that the shares remain free from direct or indirect charges during this period. This disclosure is significant for shareholders as it indicates the promoters' holdings are not pledged, which reduces potential risk regarding ownership stability.

The filing was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The communication was addressed to BSE Ltd. and the National Stock Exchange of India Ltd. on April 2, 2026. The declaration was submitted on behalf of the promoters by Harish Kamath, Corporate Counsel & Company Secretary of Ipca Laboratories Ltd.

Promoter Details

The annexure accompanying the declaration identifies the entities classified as promoters and persons acting in concert (PAC).

The document specifies that Ipca Laboratories Limited is the sole promoter listed in the annexure. A copy of the declaration was also forwarded to Unichem Laboratories and its Audit Committee of Board of Directors for their records.

Unichem Laboratories Limited has scheduled its 63rd Annual General Meeting for Tuesday, 11th August 2026 at 3:30 p.m. (IST) through Video Conference. The meeting will transact business including the adoption of financial statements for the year ended 31st March 2026, the re-appointment of Mr. Pabitrakumar Bhattacharyya as Managing Director and CEO, and the ratification of remuneration payable to Cost Auditors. Remote e-voting will be available from Friday, 7th August 2026 at 9:00 a.m. to Monday, 10th August 2026 at 5:00 p.m., with the record date for shareholder eligibility set as Tuesday, 4th August 2026.

Re-appointment of Managing Director

The Board has recommended the re-appointment of Mr. Pabitrakumar Bhattacharyya as Managing Director and CEO for a further period of three years with effect from 10th August 2026. His remuneration package includes a basic salary of ₹20,00,000 per month, subject to a ceiling of ₹28,00,000 per month, and a commission not exceeding 1% of net profits. During his tenure since August 2023, the company reported an 84% growth in standalone revenue and a 131% increase in formulation manufacturing volume, while the expense-to-revenue ratio improved from 66% to 41%.

Financial Performance

The company's financial results for FY 2025-26 show a consolidated net profit of ₹252.84 crores, compared to ₹137.52 crores in the previous year. Consolidated revenue from operations rose to ₹2,201.85 crores from ₹2,110.97 crores. The standalone net profit for the year stood at ₹158.94 crores. The following table summarizes the key financial metrics:

Operational and Sustainability Highlights

During FY 2026, the company manufactured approximately 9.4 billion tablets/capsules. It achieved a 73% reduction in Scope 1 GHG emissions compared to its 2022 baseline and a 10% reduction in Scope 2 GHG emissions. A captive solar power plant of 8 MW capacity is under implementation in Maharashtra. Total R&D expenditure for the year was ₹107.02 crores, representing 7.58% of turnover. The workforce stood at 2,815 employees as of 31st March 2026. No dividend has been recommended for FY 2026 to conserve resources.

Corporate Governance and Shareholding

As of 31st March 2026, the Board comprised six Directors. Dr. (Ms.) Swati Patankar was appointed as an Independent Director effective 5th February 2026. Promoters and persons acting in concert held 70.22% of the paid-up share capital, with Ipca Laboratories Limited holding 52.67%. The company's long-term credit rating was reaffirmed by ICRA at A+ with a stable outlook.